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T he nonprofit European Society for Clinical and Economic Aspects of Os-teoporosis and Osteoarthritis (ESCEO) fosters interaction between clin-ical scientists, the pharmaceutical industry, regulators, and health policy
makers to optimize management of osteoporosis and osteoarthritis within a
comprehensive perspective of health resource utilization. In 2008, it issued
guidance to help practitioners harmonize their prevailing national health eco-
nomies with the latest evidence-based medicine findings. Using FRAX®, a
Web-based World Health Organization tool that provides fracture probability
algorithms, the ESCEO guidelines select treatment candidates based not on
threshold bone mineral density (BMD), but on individual 10-year absolute frac-
ture risk informed by clinical risk factors and age. Decisions to treat can then
be modulated by the efficacy, cost, and side effects of treatment and on na-
tional health authorities’ willingness to pay, making them scientifically robust,
ethically correct, and economically sound. However, BMD retains its role as a
marker of treatment response, most notably with strontium ranelate, which
uniquely inhibits bone resorption while stimulating bone formation: changes
in total hip or femoral neck BMD account for up to 74% of antifracture effi-
cacy with strontium ranelate versus only 16%with bisphosphonates. Once the
FRAX® tool identifies a patient as warranting osteoporosis treatment, stron-
tium ranelate can be prescribed regardless of the level of risk identified by
the algorithm. It is currently the only compound to show antifracture efficacy
in such a widely scattered range of patients and absolute fracture risk.
Medicographia. 2010;32:67-70 (see French abstract on page 70)
What are the objectives of the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)?
T he European Society for Clinical and Economic Aspects of Osteoporosis andOsteoarthritis (ESCEO) is a not-for-profit organization dedicated to fosteringclose interaction between clinical scientists dealing with rheumatic disorders,
the pharmaceutical industry developing new compounds in this field, regulators re-
sponsible for the registration of such drugs, and health policy makers to integrate the
management of osteoporosis and osteoarthritis within a comprehensive perspec-
tive of health resources utilization. The objective of the ESCEO is to provide practi-
tioners with the latest clinical and economic information, allowing them to organize
their daily practice; to provide an evidence-based medicine perspective with eco-
nomic perception; and to remain at the forefront of science. The ESCEO Scientific
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The previous dichotomous se-
lection [of patients who deserve
to be treated], based only on a
threshold of bone mineral density,
will be replaced by the assess-
ment of the individual 10-year ab-
solute risk of fracture. Based on
this evaluation of the absolute
fracture risk and also on the will-
ingness to pay of national or re-
gional health authorities for the
management of osteoporosis, the
selection of patients to be treated
will soon become scientifically
robust, ethically correct, and eco-
nomically sound.”
‘‘
I N T E R V I E W
MEDICOGRAPHIA, Vol 32, No. 1, 2010 National implementation of the ESCEO guidance – Reginster68
Advisory Board is currently chaired by Pro-
fessor René Rizzoli, one of the most promi-
nent figures in the field of osteoporosis. Sev-
eral working groups and expert consensus
meetings have been and will be organized
to provide practitioners with a clear synthe-
sis of the most up-to-date science in various
fields of interest, including—but not exhaus-
tively—calcium and vitamin D requirements
for postmenopausal women, osteonecrosis
of the jaw linked to bisphosphonate use,
adverse dermatological reactions with anti-
osteoporosis treatments, the use of symp-
tomatic slow-acting drugs for the manage-
ment of osteoarthritis, the management of
osteoporosis in the very elderly, and sub-
trochanteric fractures after long-term use of
bisphosphonates. Furthermore, the ESCEO
is the proud organizer of the European Con-
gress on Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ECCEO),
the largest event fully dedicated to the clin-
ical and economic aspects of the management of osteoporo-
sis and osteoarthritis worldwide. The last congress took place
in Athens, Greece, and saw more than 4200 delegates gath-
ered. The next ECCEO Congress will be a joint venture with
the International Osteoporosis Foundation (IOF). Together
they will organize the IOF World Congress on Osteoporosis –
ECCEO 10 Congress, which will take place in Florence, Italy,
from May 5-8, 2010. All the information regarding this event
can be obtained at: http://www.iofwco-ecceo10.org.
What changes will the ESCEO guidance bring to
the diagnosis of osteoporosis?
In 1997, the European Foundation for Osteoporosis andBone Disease (which later joined the International Federa-tion for Societies on Skeletal Diseases to form the Interna-
tional Osteoporosis Foundation) published guidelines for the
diagnosis and management of osteoporosis. At that time, the
diagnosis of osteoporosis was based on the World Health
Organization (WHO) operational definition of osteoporosis, ie,
a T-score of bone mineral density (BMD) measured by dual-
energy x-ray absorptiometry below –2.5 at the lumbar spine
or at the total hip. Since then, there have been significant ad-
vances in the field of osteoporosis. These include the devel-
opment of many new techniques for measuring bone mineral,
improved methods of assessing fracture risk, and new treat-
ments that have been shown to significantly reduce the risk
of fractures at vulnerable sites. The objective of the new guid-
ance document published by the ESCEO is to incorporate
these new scientific developments and to provide a new con-
cept of the selection of patients who deserve to be treated.
The previous dichotomous selection, based only on a thresh-
old of bone mineral density, will be replaced by the assess-
ment of the individual 10-year absolute risk of fracture. Based
on this evaluation of the absolute fracture risk and also on the
willingness to pay of national or regional health authorities for
the management of osteoporosis, the selection of patients to
be treated will soon become scientifically robust, ethically cor-
rect, and economically sound.
What are the treatment modalities recommended
in ESCEO guidance?
T he effect of major pharmacological interventions on ver-tebral and hip fracture risk have been summarized inthe ESCEO document. Currently, the most frequently
used treatments for postmenopausal osteoporosis include
inhibitors of bone resorption (ie, bisphosphonates, selective
estrogen receptor modulators, and hormone replacement
therapy), stimulators of bone formation (peptides from the
parathyroid hormone family), and, more recently, strontium
ranelate, a chemical entity that has a unique mode of action
that concomitantly inhibits bone resorption, while stimulating
bone formation (Table I).1 The ESCEO guidance document
recommends the selection of a treatment option based on
SELECTED ABBREVIATIONS AND ACRONYMS
BMD bone mineral density
ECCEO European Congress on Clinical and Economic Aspects
of Osteoporosis and Osteoarthritis
ESCEO European Society for Clinical and Economic Aspects
of Osteoporosis and Osteoarthritis
IOF International Osteoporosis Foundation
WHO World Health Organization
Effect on Effect on
vertebral fracture risk nonvertebral fracture risk
Established Established
Osteoporosis osteoporosis* Osteoporosis osteoporosis*
Alendronate + + NA + (including hip)
Risedronate + + NA + (including hip)
Ibandronate NA + NA +†
Zoledronic acid + + NA NA (+)‡
HRT + + + +
Raloxifene + + NA NA
Teriparatide and PTH NA + NA +
Strontium ranelate + + + (including hip) + (including hip)
*Women with a prior vertebral fracture.
† In subsets of patients.
‡Mixed group of patients with or without prevalent vertebral fractures.
+ = effective drug.
Table I. Comparison of the antifracture efficacy of common osteoporosis treatments.
Antifracture efficacy of the most frequently used treatments for postmenopausal osteoporosis when
given with calcium and vitamin D, as derived from randomized controlled trials.
Abbreviations: HRT, hormone replacement therapy; NA, no evidence available; PTH, parathyroid hormone.
Adapted from reference 1: Kanis JA, Burlet N, Cooper C, et al. Osteoporos Int. 2008;19:399-428.
Copyright © 2008, International Osteoporosis Foundation and National Osteoporosis Foundation.
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its ability to reduce fractures at various skeletal sites (includ-
ing hip) and in the population being specifically considered
(ie, osteopenia, osteoporosis, or severe osteoporosis).
How can we monitor treatment efficacy with
respect to the different therapeutic classes?
Monitoring of treatment can be done with biochemicalmarkers of bone turnover or bonemineral density as-sessment. Whether the long-term antifracture effi-
cacy of antiosteoporotic drugs is dependent on the extent to
which treatment can increase or maintain BMD is controver-
sial. Meta-regressions, based on summary statistics, demon-
strate a stronger correlation between change in BMD and frac-
ture risk reduction than results based on individual patient data.
For bisphosphonates, 16% of the vertebral fracture risk re-
duction after treatment with alendronate was attributed to an
increase in BMD at the lumbar spine. Larger increases in BMD
at both the spine and hip observed with alendronate were
associated with greater reductions in the risk of nonvertebral
fractures. However, for patients treated with risedronate or
raloxifene, changes in BMD predict the degree of reduction
in vertebral or nonvertebral fractures even more poorly. For
bone-forming agents, increases in BMD account for approx-
imately one third of the vertebral fracture risk reduction with
teriparatide. A larger proportion (up to 74%) of the antifracture
efficacy of strontium ranelate is explained by changes in total
hip or femoral neck BMD. Strontium ranelate appears to be
the first agent for which BMDmeasurement after one year can
be used as a valid tool for monitoring the long-term response
to treatment. For markers of bone turnover, a significant asso-
ciation has been reported between the short-term decrease
and the absolute level of markers of bone turnover with the
use of antiresorptive agents, on the one hand, and the mag-
nitude of the reduction of the risk of vertebral and nonverte-
bral fractures, on the other hand. During bone-forming therapy
with teriparatide, serum P1NP increases two-to-three–fold
within 1 to 3 months, a change that correlates with a subse-
quent increase in BMD.
With the advent of FRAX®, should case finding
strategy be adapted to take clinical risk factors
into account?
A s of today, there is no universally accepted policy forpopulation screening in Europe to identify patients withosteoporosis or those at high risk of fracture. In the
absence of such policies, patients are identified opportunis-
tically using a case-finding strategy based on the finding of a
previous fragility fracture or the presence of significant risk fac-
tors (Table II).1 The discovery that the presence of clinical risk
factors and age modulate risk (and therefore cost-effective-
ness) reinforces the view that treatment should be directed on
the basis of fracture probability, rather than on a single BMD
threshold. Risk factors that are used for clinical assessment
include age, sex, low body mass index, previous fragility frac-
ture, parental history of hip fracture, glucocorticoid treatment,
current smoking, increased alcohol intake, and secondary
causes of osteoporosis.
How will FRAX® impact health economics?
T here is an increased need for management strategiesto be placed in an appropriate health economic per-spective for guideline development and for reimburse-
ment. Algorithms that integrate the weight of clinical risk fac-
tors for fracture risk, with or without information on BMD, have
been developed by the WHO Collaborating Center for Meta-
bolic Bone Diseases in Sheffield, England. This algorithm,
FRAX®, calculates the 10-year probability of hip fracture or ma-
jor osteoporotic fracture. Probabilities can be computed for an
index of European countries, categorized for different levels
of risk. The intervention threshold can be defined as a fracture
probability at which intervention becomes acceptable. Deci-
sions about the need for treatment depend not only upon the
fracture probability, but also on efficacy, costs, side effects of
treatment, and willingness to pay. Developments in the ability
to assess fracture probability in individuals rather than in pop-
Table II. Clinical risk factors used for the assessment of fracture
probability.
After reference 1: Kanis JA, Burlet N, Cooper C, et al. Osteoporos Int. 2008;





Low body mass index
Previous fragility fracture, particularly of the hip, wrist, and
spine (including morphometric vertebral fractures)
Parental history of hip fracture
Glucocorticoid treatment (>5 mg prednisolone daily or equiva-
lent for 3 months or more)
Current smoking
Alcohol intake of 3 or more units daily
Secondary causes of osteoporosis
Rheumatoid arthritis
Untreated hypogonadism in men and women, eg, prema-
ture menopause, bilateral oophorectomy or orchidec-
tomy, anorexia nervosa, chemotherapy for breast cancer,
and hypopituitarism
Inflammatory bowel disease, eg, Crohn’s disease and ulcera-
tive colitis (it should be noted that the risk is partly depen-
dent on the use of glucocorticoids, but an independent
risk remains after adjustment for glucocorticoid exposure)
Prolonged immobility, eg, spinal cord injury, Parkinson’s dis-
ease, stroke, muscular dystrophy, ankylosing spondylitis
Organ transplantation
Type 1 diabetes
Thyroid disorders, eg, untreated hyperthyroidism, over-
treated hypothyroidism
Chronic obstructive pulmonary disease
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ulations provide new challenges for the health economic eval-
uation of interventions (Figure 1).2 These developments mean
that previous estimates of intervention threshold based on
cost-effectiveness need to be revised using models that in-
tegrate the weights of influence of different clinical risk factors
on the risk of fracture and death.
How does Protelos’ effectiveness
independent of the level of risk factors
represent an advantage for practitioners?
Strontium ranelate has shown an antifracture ef-ficacy at all skeletal sites, including spine, non-spine, and hip. It is the only compound to have
so far shown antifracture efficacy at the hip level af-
ter five years of treatment in a preplanned, place-
bo-controlled, double-blind, randomized study. The
antifracture efficacy of strontium ranelate has also
been tested across a wide scatter of populations,
including early postmenopausal, osteopenic, osteo-
porotic, and severe osteoporotic patients, and sub-
jects over the age of 80. Similarly, the ability of stron-
tium ranelate to decrease the risk of fracture is not
influenced by the presence or absence of various
risk factors for fracture, including—but not exhaus-
tively—the severity of prevalent fractures, the num-
ber of prevalent fractures, being a current smoker,
low body mass index, parental history of fracture,
and the level of bone turnover at baseline. Strontium
ranelate is currently the only compound that has
shown antifracture efficacy in such a widely scat-
tered range of patients and absolute fracture risk.
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MISE EN PLACE NATIONALE DES RECOMMANDATIONS DE L’ESCEO ET SES CONSÉQUENCES
L’organisation à but non lucratif ESCEO, (European Society for Clinical and Economic aspects of Osteoporosis and
Osteoarthritis), encourage les relations entre cliniciens, industrie pharmaceutique, régulateurs et administrateurs de
santé afin d’optimiser la prise en charge de l’ostéoporose et de l’arthrose dans le vaste contexte de l’utilisation des
ressources de santé. En 2008, des recommandations furent mises en place pour aider les médecins à harmoniser leurs
économies de santé nationales avec les données EBM (evidence-based medicine = médecine basée sur les preuves)
les plus récentes. Les recommandations de l’ESCEO utilisant FRAX® (outil Internet de l’OMS calculant des algorithmes
de probabilité de fractures), sélectionnent les candidates au traitement non sur une valeur-seuil de la DMO (densité
minérale osseuse) mais sur le risque absolu de fracture d’un individu à 10 ans, basé sur les facteurs de risque cliniques
et sur l’âge. Les décisions de traiter peuvent ensuite être modulées selon l’efficacité, le coût et les effets secondaires
du traitement tout en tenant compte de l’accord ou non des autorités nationales de santé à en couvrir les frais. C’est
à ces conditions que les décisions seront scientifiquement valables, éthiquement correctes et économiquement saines.
La DMO garde néanmoins son rôle de marqueur dans la réponse au traitement, surtout avec le ranélate de strontium
qui inhibe la résorption osseuse et stimule la formation osseuse de façon unique : les modifications de la DMO au ni-
veau de la hanche totale ou du col fémoral comptent pour 74 % dans l’efficacité antifracturaire du ranélate de stron-
tium versus seulement 16 % avec les bisphosphonates. Une fois une patiente identifiée par FRAX® comme ayant be-
soin d’être traitée, le ranélate de strontium peut être prescrit quel que soit le niveau de risque identifié par l’algorithme.
C’est actuellement le seul composé à avoir une efficacité antifracturaire sur un tel éventail de patientes et sur un
risque absolu de fracture si largement dispersé.
Keywords: ECCEO; ESCEO; osteoporosis; osteoarthritis; IOF; bone mineral density; FRAX®






























Figure 1. The health impact of osteoporosis versus that of other diseases.
The relative burdens of a selection of noncommunicable diseases in Europe estimated using
disability-adjusted life years (DALYs).
Abbreviations: BPH, benign prostatic hyperplasia; COPD, chronic obstructive pulmonary dis-
ease; IHD, ischemic heart disease; OA, osteoarthritis; RA, rheumatoid arthritis.
Modified from reference 2: Johnell O, Kanis JA. Osteoporos Int. 2006;17:1726-1733. Copy-
right © 2006, International Osteoporosis Foundation and National Osteoporosis Foundation.
